Swissmedic OKs Celgene's Revlimid for treatment of rare blood cancer
This article was originally published in Scrip
Executive Summary
The Swiss agency for Therapeutic Products (SwissMedic) has approved Celgene's immunomodulating anticancer drug, Revlimid (lenalidamide), for use in patients with transfusion-dependent anaemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.